Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP Trial: Short-Course Outpatient Amoxicillin for Pediatric Streptococcal Pharyngotonsillitis
2026-525355-93-00Phase 3Authorised
- Sponsor
- Fundación para la Investigación Biomédica Hospital Universitario Niño Jesús
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amoxicillin in streptococcal pharyngitis and streptococcal tonsillopharyngitis (2 arms), sponsored by Fundación para la Investigación Biomédica Hospital Universitario Niño Jesús. Primary endpoint: Relapse within 15 days after completing antibiotic regimen. Planned start Jun 2026; status: authorised.
02
Drugs
amoxicillin
03
Conditions
streptococcal pharyngitisstreptococcal tonsillopharyngitis
Beyond the preview
Go deeper on 2026-525355-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525355-93-00.